CD20 Antibody (LT20) [Allophycocyanin] Summary
Normal human lymphocytes from lymph node.
The LT20 reacts with CD20 (Bp35), a 33-37 kDa non-glycosylated membrane receptor with four transmembrane domains, expressed on B lymphocytes (it is lost on plasma cells), follicular dendritic cells, and at low levels on peripheral blood T lymphocytes.
IgG2a
Monoclonal
Mouse
MS4A1
Unpurified
Test in a species/application not listed above to receive a full credit towards a future purchase.
Learn about the Innovators Reward
Applications/Dilutions
- Flow Cytometry 10 ul/100 ul of whole blood or 10^6 cells in suspension
Reactivity Notes
Human.
Packaging, Storage & Formulations
Store at 4C in the dark.
PBS and 0.2% (w/v) high grade BSA (protease free)
15mM Sodium Azide
Unpurified
Alternate Names for CD20 Antibody (LT20) [Allophycocyanin]
- B1
- B-lymphocyte antigen CD20
- B-lymphocyte cell-surface antigen B1
- B-lymphocyte surface antigen B1
- Bp35
- Bp35MGC3969
- CD20 antigen
- CD20 receptor
- CD20
- CD20S7
- CVID5
- LEU-16
- Leukocyte surface antigen Leu-16
- Ly-44
- Membrane-spanning 4-domains subfamily A member 1
- membrane-spanning 4-domains, subfamily A, member 1
- MS4A1
- MS4A2
- S7
Background
CD20 is a cell surface 33-37 (depending on the degree of phosphorylation) kDa non-glycosylated surface phosphoprotein expressed on mature and most malignant B cells, but not stem cells or plasma cells (low number of the CD20 has been also detected on a subpopulation of T lymphocytes and it can be expressed on follicular dendritic cells). Its expression on B cells is synchronous with the expression of surface IgM. CD20 regulates transmembrane calcium conductance (probably functioning as a component of store-operated calcium channel), cell cycle progression and B-cell proliferation. It is associated with lipid rafts, but the intensity of this association depends on extracellular triggering, employing CD20 conformational change and/or BCR (B cell antigen receptor) aggregation. After the receptor ligation, BCR and CD20 colocalize and then rapidly dissociate before BCR endocytosis, whereas CD20 remains at the cell surface. CD20 serves as a useful target for antibody-mediated therapeutic depletion of B cells, as it is expressed at high levels on most B-cell malignancies, but does not become internalized or shed from the plasma membrane following mAb treatment.
Limitations
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.